Market Spotlight: NHL: Peripheral T-cell lymphoma (PTCL)
|出版日期||內容資訊||英文 50 Pages
|焦點市場分析:末梢性T細胞淋巴瘤 (PTCL) Market Spotlight: NHL: Peripheral T-cell lymphoma (PTCL)|
|出版日期: 2019年12月23日||內容資訊: 英文 50 Pages||
本報告提供全球末梢性T細胞淋巴瘤 (PTCL)的治療藥的市場調查，彙整與疾病的背景·概要，罹患數的十年預測，已上市藥物核准趨勢，主要的開發平台概要，主要的資本交易趨勢 (授權合約，資產收購等)，主要藥物的銷售額預測，專利趨勢，臨床試驗狀況等資料。
This Market Spotlight report covers the Peripheral T-Cell Lymphoma market, comprising key marketed and pipeline drugs, clinical trials, upcoming events, probability of success, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Datamonitor Healthcare estimates that in 2017, there were approximately 19,950 incident cases of peripheral T-cell lymphoma (PTCL) worldwide, and forecasts that number to increase to 23,880 incident cases by 2026. It is estimated that the majority of diagnosed cases were in males in 2017. The incidence of PTCL is highest among older individuals aged 60+ years. The approved drugs in the PTCL space focus on a wide variety of targets. These drugs are administered via the intravenous and oral routes.
The majority of industry-sponsored drugs in active clinical development for PTCL are in Phase II. Therapies in development for PTCL focus on a wide variety of targets. These therapies are administered via the oral and intravenous routes.
High-impact upcoming events for drugs in the PTCL space comprise topline Phase II trial results for Zinapar and IPH4102, Phase II updated trial results for CS1001, and an expected supplemental CHMP opinion for Adcetris.
The overall likelihood of approval of a Phase I hematologic asset is 9.9%, and the average probability a drug advances from Phase III is 59.4%. Drugs, on average, take 8.8 years from Phase I to approval, compared to 9.3 years in the overall oncology space.
There have been 15 licensing and asset acquisition deals involving PTCL drugs during 2014-19. The $327.5m license and supply agreement signed in 2019 between Rigel Pharmaceuticals and Grifols, to commercialize fostamatinib disodium hexahydrate in all potential indications, was the largest deal.
The distribution of clinical trials across Phase I-IV indicates that the vast majority of trials for PTCL have been in the early and mid-phases of development, with 93% of trials in Phase I-II, and only 7% in Phase III-IV.
The US has a substantial lead in the number of PTCL clinical trials globally. The UK and France lead the major EU markets, while Japan has the top spot in Asia.
Clinical trial activity in the PTCL space is dominated by completed trials. Bristol-Myers Squibb has the highest number of completed clinical trials for PTCL, with nine trials.
Bristol-Myers Squibb leads industry sponsors with the highest overall number of clinical trials for PTCL, followed by Spectrum Pharmaceuticals.